Immunization against poliomyelitis: risk/benefit/cost in a changing context.
Salk. J J
Key Findings
- Both killed and live polio vaccines have small but real risks, such as the vaccine virus reaching the central nervous system.
- The likelihood of these risks varies between developed and developing nations.
- Complete eradication of polio (wild and vaccine strains) would remove vaccine‑related risks.
Practical Outcomes
- For biohackers focused on longevity and performance, this study offers no direct actionable insight. It is primarily relevant to public health policy rather than personal health optimization or peptide use.
Summary
The paper looks at the pros and cons of the two types of polio vaccines (killed and live) and how their risks differ in rich and poor countries. It talks about rare cases where the vaccine virus might get into the brain or fail to protect, and mentions that getting rid of both wild and vaccine viruses would eliminate these risks.
Abstract
Benefit/risk factors in immunization against poliomyelitis are examined from the viewpoint of the relative risk and efficacy of killed and live poliovirus vaccines in the currently changing contexts of poliomyelitis prevalence in developed and developing countries. Risk factors include virus of vaccine origin gaining access to the CNS, and failure of the vaccine to immunize. Data are presented to illustrate the degree to which the respective risks occur in developed and developing countries. The ultimate elimination of risk by eradication of wild and vaccine virus from the population is discussed.
Study Information
pubmed
1979